Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19

Saved in:
Bibliographic Details
Published inFrontiers in medicine Vol. 8; p. 743325
Main Authors Alape-Girón, Alberto, Moreira-Soto, Andrés, Arguedas, Mauricio, Brenes, Hebleen, Buján, Willem, Corrales-Aguilar, Eugenia, Díaz, Cecilia, Echeverri, Ann, Flores-Díaz, Marietta, Gómez, Aarón, Hernández, Andrés, Herrera, María, León, Guillermo, Macaya, Román, Molina-Mora, José Arturo, Mora, Javier, Narayanan, Aarthi, Sanabria, Alfredo, Sánchez, Andrés, Sánchez, Laura, Segura, Álvaro, Segura, Eduardo, Solano, Daniela, Soto, Claudio, Stynoski, Jennifer L., Vargas, Mariángela, Villalta, Mauren, Drexler, Jan Felix, Gutiérrez, José María
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 06.09.2021
Subjects
convalescent plasma
COVID-19
heterologous antibodies
hyperimmune polyclonal antibodies
Medicine
passive immunotherapy
SARS-CoV-2
COVID-19
SARS-CoV-2
heterologous antibodies
hyperimmune polyclonal antibodies
passive immunotherapy
convalescent plasma
monoclonal antibodies
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Zhiliang Hu, Nanjing Second Hospital, China
This article was submitted to Infectious Diseases - Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine
Reviewed by: Thierry Burnouf, Taipei Medical University, Taiwan; Leonardo M. R. Ferreira, Medical University of South Carolina, United States
ISSN:2296-858X
2296-858X
DOI:10.3389/fmed.2021.743325